NUC-1031: Phase I data

Interim data from the open-label, U.K. Phase I ProGem1 trial in 11 heavily pretreated patients with advanced solid tumors showed that escalating doses of IV NUC-1031 led to 6 cases of stable disease. NUC-1031 was well tolerated. The most common grade 1/2 adverse events reported were taste disturbance, dysgeusia, anorexia, constipation and elevated liver function tests. Patients received 1,000 and 2,000 mg/m 2 IV NUC-1031 on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles, or 500 and 1,000 mg/m 2 IV NUC-1031 on days 1, 5, 8, 12, 15 and 19 of a 28-day cycle for up to 6 cycles. The trial will continue into the dose-expansion phase in which patients will receive the recommended Phase II dose of NUC-1031. ...